Lulizumab pegol

Generic Name: Lulizumab pegol

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1421830-13-8

Unique Ingredient Identifier: LCT264LTYE

Background: Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Phase 1

Completed

Conditions: Living-Donor Kidney Transplant
Kidney Transplant Recipients

Interventions: Biological: lulizumab pegol
Biological: antithymocyte globulin (rabbit)
Drug: methylprednisolone
Biological: tocilizumab
Drug: Prednisone
Drug: everolimus
Biological: belatacept
Drug: mycophenolate mofetil
Drug: mycophenolic acid

First Posted Date: 2019-08-26

Last Posted Date: 2024-10-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT04066114

Locations: 🇺🇸
Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States
🇺🇸
University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States
🇺🇸
University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States

and more 4 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy